NO975977L - Substituted purine derivatives, processes for their preparation and use - Google Patents
Substituted purine derivatives, processes for their preparation and useInfo
- Publication number
- NO975977L NO975977L NO975977A NO975977A NO975977L NO 975977 L NO975977 L NO 975977L NO 975977 A NO975977 A NO 975977A NO 975977 A NO975977 A NO 975977A NO 975977 L NO975977 L NO 975977L
- Authority
- NO
- Norway
- Prior art keywords
- processes
- preparation
- purine derivatives
- substituted purine
- substituted
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE19653646A DE19653646A1 (en) | 1996-12-20 | 1996-12-20 | Substituted purine derivatives, processes for their preparation, agents containing them and their use |
Publications (3)
Publication Number | Publication Date |
---|---|
NO975977D0 NO975977D0 (en) | 1997-12-19 |
NO975977L true NO975977L (en) | 1998-06-22 |
NO314583B1 NO314583B1 (en) | 2003-04-14 |
Family
ID=7815761
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19975977A NO314583B1 (en) | 1996-12-20 | 1997-12-19 | Substituted purine derivatives, methods of preparation and pharmaceutical compositions containing them |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP0853084B1 (en) |
JP (1) | JP4620190B2 (en) |
KR (1) | KR19980064655A (en) |
CN (2) | CN1495184A (en) |
AR (1) | AR010700A1 (en) |
AT (1) | ATE404562T1 (en) |
AU (1) | AU728865B2 (en) |
BR (1) | BR9706387A (en) |
CA (1) | CA2225366C (en) |
CZ (1) | CZ294437B6 (en) |
DE (2) | DE19653646A1 (en) |
HK (1) | HK1012190A1 (en) |
HU (1) | HUP9702507A3 (en) |
ID (1) | ID19254A (en) |
IL (1) | IL122642A0 (en) |
NO (1) | NO314583B1 (en) |
NZ (1) | NZ329431A (en) |
PL (1) | PL323969A1 (en) |
RU (1) | RU2228335C2 (en) |
TR (1) | TR199701647A3 (en) |
TW (1) | TW523515B (en) |
ZA (1) | ZA9711317B (en) |
Families Citing this family (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6420558B1 (en) | 1998-04-09 | 2002-07-16 | Meiji Seika Kaisha, Ltd. | Aminopiperidine derivates as integrin αvβ3 antagonists |
JP2002533404A (en) | 1998-12-23 | 2002-10-08 | ジー・ディー・サール・アンド・カンパニー | Methods of using integrin antagonists and radiation therapy as combination therapy in the treatment of neoplasia |
UA71945C2 (en) | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
JP3270834B2 (en) | 1999-01-27 | 2002-04-02 | ファイザー・プロダクツ・インク | Heteroaromatic bicyclic derivatives useful as anticancer agents |
EP1065208A1 (en) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Substituted purine derivatives as inhibitors of cell adhesion |
EP1065207A1 (en) * | 1999-07-02 | 2001-01-03 | Aventis Pharma Deutschland GmbH | Naphthyridine derivatives, processes for their preparation, their use, and pharmaceutical compositions comprising them |
WO2001010844A1 (en) | 1999-08-05 | 2001-02-15 | Meiji Seika Kaisha, Ltd. | φ-AMINO-α-HYDROXYCARBOXYLIC ACID DERIVATIVES HAVING INTEGRIN αvβ3 ANTAGONISM |
EP1176145A1 (en) * | 2000-07-28 | 2002-01-30 | Aventis Pharma Deutschland GmbH | Novel guanidino derivatives as inhibitors of cell adhesion |
DE10042655A1 (en) | 2000-08-31 | 2002-03-14 | Aventis Pharma Gmbh | Process for the preparation of inhibitors of cell adhesion |
KR100438820B1 (en) * | 2001-03-05 | 2004-07-05 | 삼성코닝 주식회사 | Method for manufacturing compound semiconductor substrate of III-V group |
CN1247258C (en) | 2001-04-24 | 2006-03-29 | 默克专利有限公司 | Combination therapy using anti-angiogenic agents and tnfa |
FR2847254B1 (en) * | 2002-11-19 | 2005-01-28 | Aventis Pharma Sa | NOVEL VITRONECTIN RECEPTOR ANTAGONIST DERIVATIVES, PROCESS FOR PREPARING THEM, THEIR APPLICATION AS MEDICAMENTS AND THE PHARMACEUTICAL COMPOSITIONS REFLECTING THEM |
FR2870541B1 (en) | 2004-05-18 | 2006-07-14 | Proskelia Sas | ANTIGONISTIC PYRIMIDINE DERIVATIVES OF VITRONECTIN RECEPTOR |
UA87854C2 (en) | 2004-06-07 | 2009-08-25 | Мерк Энд Ко., Инк. | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators |
ES2521679T3 (en) | 2006-01-18 | 2014-11-13 | Merck Patent Gmbh | Specific therapy using integrin ligands for cancer treatment |
JP2010516645A (en) | 2007-01-18 | 2010-05-20 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | Specific therapies and drugs using integrin ligands to treat cancer |
ES2677246T3 (en) | 2007-10-11 | 2018-07-31 | Daiichi Sankyo Company, Limited | Antibody that targets Siglec-15 osteoclast-related protein |
NZ586129A (en) * | 2007-11-14 | 2012-06-29 | Myrexis Inc | Therapeutic compounds and their use in treating diseases and disorders |
JP5653909B2 (en) | 2009-04-09 | 2015-01-14 | 第一三共株式会社 | Anti-Siglec-15 antibody |
KR20120104491A (en) | 2009-05-25 | 2012-09-21 | 메르크 파텐트 게엠베하 | Continuous administration of cilengitide in cancer treatments |
MX2013003828A (en) | 2010-10-05 | 2013-06-28 | Daiichi Sankyo Co Ltd | Antibody targeting osteoclast-related protein siglec-15. |
SG11201405966PA (en) | 2012-03-30 | 2014-11-27 | Daiichi Sankyo Co Ltd | Cdr-modified anti-siglec-15 antibody |
CN103665043B (en) | 2012-08-30 | 2017-11-10 | 江苏豪森药业集团有限公司 | A kind of tenofovir prodrug and its application in medicine |
JP6649902B2 (en) | 2014-05-30 | 2020-02-19 | ファイザー・インク | Carbonitrile derivatives as selective androgen receptor modulators |
WO2023275715A1 (en) | 2021-06-30 | 2023-01-05 | Pfizer Inc. | Metabolites of selective androgen receptor modulators |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS4730696Y1 (en) * | 1966-12-10 | 1972-09-13 | ||
JPS6396663A (en) * | 1986-10-13 | 1988-04-27 | Mita Ind Co Ltd | Electrostatic charge image developing toner |
JPS6396553A (en) * | 1986-10-14 | 1988-04-27 | Sekisui Chem Co Ltd | Packing material |
DE4129603A1 (en) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | CONDENSED 5-LOW HETEROCYCLES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THESE COMPOUNDS |
MX9207334A (en) * | 1991-12-18 | 1993-08-01 | Glaxo Inc | NUCLEIC ACIDS PEPTIDICS AND PHARMACEUTICAL FORMULATION CONTAINING THEM |
FR2700337B1 (en) * | 1993-01-11 | 1995-04-14 | Lafon Labor | Imidazopyridine-2-one derivatives, their preparation process and their use in therapy. |
US6133444A (en) * | 1993-12-22 | 2000-10-17 | Perseptive Biosystems, Inc. | Synthons for the synthesis and deprotection of peptide nucleic acids under mild conditions |
DE4405378A1 (en) * | 1994-02-19 | 1995-08-24 | Merck Patent Gmbh | Adhesion receptor antagonists |
US5554746A (en) * | 1994-05-16 | 1996-09-10 | Isis Pharmaceuticals, Inc. | Lactam nucleic acids |
US5929046A (en) * | 1994-06-08 | 1999-07-27 | Cancer Research Campaign Technology Limited | Pyrimidine and purine derivatives and their use in treating tumour cells |
US6110923A (en) * | 1994-06-22 | 2000-08-29 | Biochem Pharma Inc. | Method for treating cancer using novel substituted purinyl derivatives with immunomodulating activity |
BR9508178A (en) * | 1994-06-29 | 1997-11-18 | Smithkline Beecham Corp | Vitronectin receptor antagonists |
US5525606A (en) * | 1994-08-01 | 1996-06-11 | The United States Of America As Represented By The Department Of Health And Human Services | Substituted 06-benzylguanines and 6(4)-benzyloxypyrimidines |
WO1996020212A2 (en) * | 1994-12-28 | 1996-07-04 | Buchardt, Dorte | Peptide nucleic acid incorporating a chiral backbone |
US5977061A (en) * | 1995-04-21 | 1999-11-02 | Institute Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic | N6 - substituted nucleotide analagues and their use |
DE69632324T2 (en) * | 1995-06-07 | 2005-06-16 | PerSeptive Biosystems, Inc., Framingham | PNA-DNA CHIMESES AND PNA SYNTHESES FOR THEIR PREPARATION |
JPH1025294A (en) * | 1996-03-26 | 1998-01-27 | Akira Matsuda | Condensed heterocyclic derivative, its production and malignant tumor therapeutic agent containing the same |
JP2000507552A (en) * | 1996-03-26 | 2000-06-20 | デュポン ファーマシューティカルズ カンパニー | Aryloxy and arylthio fused pyridines, aryloxy and arylthio fused pyrimidines and derivatives thereof |
GB9613021D0 (en) * | 1996-06-21 | 1996-08-28 | Pharmacia Spa | Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors |
AU717387B2 (en) * | 1996-07-24 | 2000-03-23 | Rolf H. Berg | Peptide nucleic acids having enhanced binding affinity, sequence specificity and solubility |
US5866702A (en) * | 1996-08-02 | 1999-02-02 | Cv Therapeutics, Incorporation | Purine inhibitors of cyclin dependent kinase 2 |
-
1996
- 1996-12-20 DE DE19653646A patent/DE19653646A1/en not_active Withdrawn
-
1997
- 1997-12-12 DE DE59712958T patent/DE59712958D1/en not_active Expired - Lifetime
- 1997-12-12 EP EP97121930A patent/EP0853084B1/en not_active Expired - Lifetime
- 1997-12-12 AT AT97121930T patent/ATE404562T1/en not_active IP Right Cessation
- 1997-12-17 BR BR9706387-8A patent/BR9706387A/en not_active Application Discontinuation
- 1997-12-17 ZA ZA9711317A patent/ZA9711317B/en unknown
- 1997-12-18 CZ CZ19974114A patent/CZ294437B6/en not_active IP Right Cessation
- 1997-12-18 TR TR97/01647A patent/TR199701647A3/en unknown
- 1997-12-18 AR ARP970105996A patent/AR010700A1/en unknown
- 1997-12-18 ID IDP973919A patent/ID19254A/en unknown
- 1997-12-18 NZ NZ329431A patent/NZ329431A/en unknown
- 1997-12-18 IL IL12264297A patent/IL122642A0/en unknown
- 1997-12-18 AU AU48466/97A patent/AU728865B2/en not_active Ceased
- 1997-12-19 RU RU97121235/04A patent/RU2228335C2/en not_active IP Right Cessation
- 1997-12-19 CN CNA031009328A patent/CN1495184A/en active Pending
- 1997-12-19 NO NO19975977A patent/NO314583B1/en unknown
- 1997-12-19 CN CN97107287A patent/CN1101816C/en not_active Expired - Fee Related
- 1997-12-19 CA CA002225366A patent/CA2225366C/en not_active Expired - Lifetime
- 1997-12-19 HU HU9702507A patent/HUP9702507A3/en unknown
- 1997-12-20 PL PL97323969A patent/PL323969A1/en unknown
- 1997-12-20 KR KR1019970073883A patent/KR19980064655A/en not_active Application Discontinuation
- 1997-12-22 JP JP36553097A patent/JP4620190B2/en not_active Expired - Lifetime
-
1998
- 1998-02-11 TW TW086119133A patent/TW523515B/en not_active IP Right Cessation
- 1998-12-15 HK HK98113384A patent/HK1012190A1/en not_active IP Right Cessation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO975977L (en) | Substituted purine derivatives, processes for their preparation and use | |
NO963015L (en) | Tetracyclic derivatives, process for preparation and use | |
NO20012158D0 (en) | Substituted 2-phenylbenzimidazoles, process for preparation and use thereof | |
NO980720D0 (en) | Pyridazine-3-one derivatives, their use and intermediates for their preparation | |
IS4785A (en) | Triazole derivatives, useful in treatment | |
CY2013003I1 (en) | PHOSPHONOCHEMICAL DERIVATIVES, PROCESS FOR THEIR PREPARATION, AND USE THEREOF | |
EE04721B1 (en) | Phenylxanthine derivatives, processes for their preparation and use | |
DE69735712D1 (en) | ARYL-PYRIMIDINE DERIVATIVES | |
ATE261942T1 (en) | 6-PHENYLPYRIDINE DERIVATIVES | |
IS5353A (en) | Acyl-piperazinil-pyrimidine derivatives, their preparation and use as pharmaceuticals | |
DK0871656T3 (en) | Dolastatin derivatives, their preparation and use | |
DK1015444T3 (en) | Pyrimidine derivatives and processes for their preparation | |
DE69732576D1 (en) | TETRAHYDROBENZINDOLON DERIVATIVES | |
DK0915845T3 (en) | Acryloyl-substituted distamycin derivatives, process for their preparation and use as antitumor and antiviral agents | |
DK0922050T3 (en) | 3-descladinose-2,3-anhydroerythromycin derivatives | |
EE03682B1 (en) | Substituted benzimidazole derivatives, processes for their preparation and their use | |
NO985307L (en) | Distamycin derivatives, processes for their preparation, and their use | |
DK1025100T3 (en) | 3-substituted tetrahydropyridopyrimidinone derivatives, their preparation and their use | |
DE69524611D1 (en) | Pyrimidone DERIVATIVES | |
DK0675133T3 (en) | 13-Substituted milbemycin derivatives, their preparation and their use | |
DE69724941D1 (en) | Aminopyridine DERIVATIVES | |
EE9800333A (en) | Novel furanarylmethylidene derivatives, methods for their preparation and use in therapy | |
NO984921D0 (en) | Tienopyridine derivatives and their use | |
GR3035834T3 (en) | Benzoxazindione derivatives, process for their preparation and their use | |
DK0799238T3 (en) | 14alpha, 17alpha-C2-linked 19-nor-progesterone derivatives |